🇺🇸 LHRH Agonist in United States

17 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 20 April 2025 – 20 April 2026
• Total reports: 17

Most-reported reactions

1. Dyspnoea — 3 reports (17.65%)
2. Cough — 2 reports (11.76%)
3. Malignant Neoplasm Progression — 2 reports (11.76%)
4. Metastases To Bone — 2 reports (11.76%)
5. Metastases To Central Nervous System — 2 reports (11.76%)
6. Prostate Cancer — 2 reports (11.76%)
7. Ascites — 1 report (5.88%)
8. Blood Alkaline Phosphatase Increased — 1 report (5.88%)
9. Blood Bilirubin Increased — 1 report (5.88%)
10. Blood Glucose Increased — 1 report (5.88%)

Source database →

Frequently asked questions

Is LHRH Agonist approved in United States?

LHRH Agonist does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for LHRH Agonist in United States?

Pfizer Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.